// App-Quantinova.ai

6025 : Final results of the randomized phase II DeLOS-II trial: Induction chemotherapy (IC) followed by radiotherapy (R) vs. cetuximab (E) plus IC and R for functional larynx preservation in resectable laryngeal and hypopharyngeal cancer (LHSCC).

Researchers

Presenter

  • Andreas Dietz

Principal Investigators

  • Michael Flentje

  • Rudolf Hagen

  • Oliver Koelbl

  • Frank Schreiber

  • Volker Schilling

  • Georg Maschmeyer

  • Ursula Schroeder

  • Christian Sittel

  • Thomas Lenarz

  • Jens Peter Klussmann

  • Orlando Guntinas-Lichius

  • Claudia Rudack

  • Thomas Foerg

  • Martin Westhofen

  • Hans Juergen Welkoborsky

  • Dirk Esser

  • Swantje Held

  • Ulrich Keilholz

Medical Centers

  • University of Leipzig, Leipzig, Germany

  • Department of Otolaryngology, Head and Neck Surgery, University Hospital Leipzig, Leipzig, Germany

  • University of Wurzburg, Wurzburg, Germany

  • ENT Department University Wurzburg, Wurzburg, Germany

  • Dpt. for Radiation Oncology, University of Regensburg, Regensburg, Germany

  • ENT Department, Klinikum Kassel, Kassel, Germany

  • ENT Clinic Vivantes, Berlin, Neukoln, Germany

  • Potsdam Klinikum, Potsdam, Germany

  • ENT Department University Lubeck, Lubeck, Germany

  • ENT Department Katharinen Hospital, Stuttgart, Germany

  • ENT Department MHH Hannover, Hannover, Germany

  • ENT Department University Gieen, Gieen, Germany

  • University Hospital Jena, Head and Neck Surgery, Jena, Germany

  • ENT Department University Munster, Munster, Germany

  • Department Radiation Oncology, Vincentius Clinic, Karlsruhe, Germany

  • ENT Department University Aachen, Aachen, Germany

  • ENT Clinic, Nordstadt, Hannover, Germany

  • ENT Department, Helios Clinic, Erfurt, Germany

  • ClinAssess GmbH, Leverkusen, Germany

  • Department for Hemato-Oncology, Comprehensive Cancer Center, Charite-University Medicine, Berlin, Germany

Locations

  • Germany

Companies

  • ClinAssess GmbH

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Tumors of the head and neck

Biomarkers

  • N/A

Drug/Treatment

  • Erbitux

  • Docetaxel

  • Cisplatin

  • Roxithromycin

Outcome

  • N/A


Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT00508664

Sponsors

  • N/A

Result

  • Final